The results of MAPK PCR array studies demonstrated decreased expression levels of 6 genes after sorafenib treatment, suggesting a robust inhibitory impact of the drug on MAPK signaling in HCC cells (Fig. 2); however, 2 genes, CDK6 and JUN, were upregulated after sorafenib treatment. This evidence concerns the gene CDK6 and hepatocellular carcinoma.